ArticleFrontiers in medicine2026
Oxaliplatin-induced porto-sinusoidal vascular disease manifesting as recurrent gastroesophageal variceal hemorrhage: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porto-sinusoidal vascular disease (PSVD) is an increasingly recognized cause of non-cirrhotic portal hypertension, characterized by structural abnormalities of the portal microvasculature and hepatic sinusoids in the absence of cirrhosis. Recognized predisposing factors include immune-mediated conditions, infections and exposure to hepatic sinusoid-toxic agents, among others. We report a 44-year-old woman with a history of oxaliplatin-based chemotherapy for colon cancer who presented with recurrent hematochezia, hematemesis, and transient encephalopathy. Evaluation demonstrated portal hypertension and portal vein thrombosis; however, liver biopsy showed no cirrhosis and the hepatic venous pressure gradient (HVPG) was within normal limits. Her medication history, combined with these findings, confirmed the diagnosis of oxaliplatin-induced PSVD. This case highlights the importance of considering PSVD in patients with non-cirrhotic portal hypertension, particularly when there is a history of exposure to agents toxic to the hepatic sinusoids, such as oxaliplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.